

# Non-Interventional Post-Authorisation Safety Study (NI-PASS) as an effectiveness check of an additional Risk Minimisation Measure (aRMM) (Direct Healthcare Professional Communication [DHPC]) for Bendamustine

**First published:** 14/05/2020

**Last updated:** 02/07/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS34255

---

### Study ID

41682

---

### DARWIN EU® study

No

---

## Study countries

- ☐ France
  - ☐ Germany
  - ☐ United Kingdom
- 

## Study description

This study will be carried out to evaluate the effectiveness of an additional risk minimization measure (aRMM) (a Direct Healthcare Professional Communication DHPC letter) for bendamustine. The purpose of this study is to evaluate all-cause mortality and serious and fatal infections occurring in pre- and post-DHPC dissemination periods for new users of bendamustine during these periods, as well as for new users of other alkylating drugs similar to bendamustine (i.e. cyclophosphamide for indolent non-Hodgkin's lymphoma (iNHL), chlorambucil for chronic lymphocytic leukemia (CLL), melphalan for multiple myeloma (MM)) in populations in four European countries. Additionally, the other purpose of this study is to quantify and characterise approved and off-label use of bendamustine and other alkylating drugs similar to bendamustine (alternative treatments) in new users in pre- and post-DHPC dissemination periods in populations from four European countries.

---

## Study status

Finalised

# Research institutions and networks

## Institutions

Real World Solutions, IQVIA

- ☐ Netherlands

☐ United Kingdom (Northern Ireland)

**First published:** 28/04/2011

**Last updated:** 22/03/2024

**Institution**

**Other**

**ENCePP partner**

## Contact details

### Study institution contact

Clinical Trial Registration Department  
[clinicaltrialregistration@astellas.com](mailto:clinicaltrialregistration@astellas.com)

**Study contact**

[clinicaltrialregistration@astellas.com](mailto:clinicaltrialregistration@astellas.com)

### Primary lead investigator

Massoud Toussi

**Primary lead investigator**

## Study timelines

### Date when funding contract was signed

Planned: 09/12/2019

Actual: 09/12/2019

---

### Study start date

Planned: 30/06/2020

Actual: 26/06/2020

---

**Date of interim report, if expected**

Actual: 26/05/2021

---

**Date of final study report**

Planned: 31/03/2023

Actual: 19/04/2023

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Astellas Pharma Europe B.V.

## Study protocol

[6231-ma-3264-clrp-02-disc01-en-final-02.pdf](#)(1.6 MB)

[6231-MA-3264\\_Bendamustine NI-PASS\\_Protocol\\_v7.0-Disclosure-Redacted \(1\).pdf](#)(1.19 MB)

## Regulatory

**Was the study required by a regulatory body?**

Yes

---

**Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

## Methodological aspects

**Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Disease epidemiology

Drug utilisation

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

**Data collection methods:**

Combined primary data collection and secondary use of data

---

**Main study objective:**

To evaluate all-cause mortality and serious and fatal infections occurring in pre- and post-DHPC dissemination periods for new users of bendamustine and new users of other alkylating drugs similar to bendamustine, and to quantify and characterise approved- and off-label use of bendamustine and other alkylating drugs similar to bendamustine in new users in pre- and post-DHPC dissemination periods.

## Study Design

**Non-interventional study design**

Cohort

## Population studied

### **Short description of the study population**

The study cohort included new users of bendamustine or similar alkylating drugs for treating indolent non-Hodgkin's lymphoma (iNHL), chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) during the pre-direct healthcare professional communication (DHPC) dissemination period (01 April 2015 – 31 March 2017) or the post-DHPC dissemination period (01 September 2017 – 31 August 2019).

the study included single patient in either the bendamustine cohort or the cohort of alkylating drugs similar to bendamustine in the same period. The included patients were expected to be indicative of patients in the general population.

---

### **Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### **Estimated number of subjects**

21091

## Study design details

## Outcomes

-Study A: All-cause mortality, serious and fatal infections -Study B: Approved- and off-label use of bendamustine and alkylating drugs similar to bendamustine, -Study A: Hepatitis B reactivation, myelosuppression, use of anti-infective drugs, use of anti-infective drugs used for prophylaxis of opportunistic infections (PJP, VZV, CMV), frequency of laboratory testing for CD-4 positive T-cell levels in outpatient settings. -Study B: Concurrent use of bendamustine with rituximab, obinutuzumab, or idelalisib

---

## Data analysis plan

Study A: The incidence rates and corresponding 95% CIs of safety event outcomes will be calculated by dividing the number of observed events by person-time exposure. Results for the pre- and post- DHPC dissemination periods will be presented separately. The main study results will be stratified by country. Study B: The proportion of new users of bendamustine or alkylating drugs similar to bendamustine with any observed off-label use during the study period (pre- and post-DHPC dissemination separately) will be calculated by dividing the number of new users with any off-label use by the total number of new users, and 95% CI will be calculated. The proportion of new users of bendamustine or alkylating drugs similar to bendamustine with off-label use at the time of new use will be calculated together with 95% CIs. Results for the pre- and post-DHPC dissemination periods will be presented separately. The main study results will be stratified by country.

## Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s), other

Hospital Episodes Statistics

---

### Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Electronic healthcare records \(EHR\)](#)

[Other](#)

---

### Data sources (types), other

Physician survey

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No